TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H ( (HK:2315) ).
Biocytogen Pharmaceuticals held its first extraordinary general meeting of 2025, where several key resolutions were approved by shareholders. The meeting, conducted both physically and virtually, saw the approval of the proposed issuance of A Shares and amendments to the company’s Articles of Association, reflecting strategic moves to enhance its market presence and operational framework.
The most recent analyst rating on (HK:2315) stock is a Hold with a HK$30.00 price target. To see the full list of analyst forecasts on Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H stock, see the HK:2315 Stock Forecast page.
More about Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is a pharmaceutical company based in China, primarily focused on the development and commercialization of innovative drugs and therapeutic solutions. The company operates within the biopharmaceutical industry, targeting advancements in biotechnology and pharmaceutical research.
Average Trading Volume: 488,942
Technical Sentiment Signal: Buy
Current Market Cap: HK$13.33B
For a thorough assessment of 2315 stock, go to TipRanks’ Stock Analysis page.